Millennium Management’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $29.1M | Sell |
404,277
-49,798
| -11% | -$2.84M | 0.01% | 1259 |
|
|
2025
Q4 | $19.2M | Sell |
454,075
-91,919
| -17% | -$5.14M | 0.01% | 1620 |
|
|
2025
Q3 | $31.1M | Sell |
545,994
-103,039
| -16% | -$3.41M | 0.01% | 1228 |
|
|
2025
Q2 | $16.8M | Buy |
649,033
+496,446
| +325% | +$5.57M | 0.01% | 1759 |
|
|
2025
Q1 | $1.56M | Sell |
152,587
-149,076
| -49% | -$1.95M | ﹤0.01% | 4008 |
|
|
2024
Q4 | $4.21M | Sell |
301,663
-35,785
| -11% | -$631K | ﹤0.01% | 2974 |
|
|
2024
Q3 | $6.58M | Buy |
337,448
+26,817
| +9% | +$511K | ﹤0.01% | 2592 |
|
|
2024
Q2 | $5.78M | Buy |
310,631
+111,661
| +56% | +$2.35M | ﹤0.01% | 2590 |
|
|
2024
Q1 | $2.79M | Buy |
198,970
+92,560
| +87% | +$969K | ﹤0.01% | 3441 |
|
|
2023
Q4 | $902K | Buy |
106,410
+27,039
| +34% | +$205K | ﹤0.01% | 4241 |
|
|
2023
Q3 | $709K | Sell |
79,371
-218,684
| -73% | -$2.11M | ﹤0.01% | 4434 |
|
|
2023
Q2 | $2.57M | Buy |
298,055
+294,305
| +7,848% | +$3.14M | ﹤0.01% | 3255 |
|
|
2023
Q1 | $40K | Sell |
3,750
-37,111
| -91% | -$1.12M | ﹤0.01% | 5689 |
|
|
2022
Q4 | $1.39M | Buy |
40,861
+30,300
| +287% | +$1.47M | ﹤0.01% | 3865 |
|
|
2022
Q3 | $507K | Buy |
+10,561
| New | +$628K | ﹤0.01% | 4961 |
|
|
2022
Q2 | – | Sell |
-123,642
| Closed | -$10M | – | 7318 |
|
|
2022
Q1 | $10M | Buy |
123,642
+40,928
| +49% | +$6.06M | 0.01% | 2170 |
|
|
2021
Q4 | $16.8M | Buy |
82,714
+38,917
| +89% | +$8.44M | 0.01% | 1612 |
|
|
2021
Q3 | $11.8M | Buy |
43,797
+5,371
| +14% | +$1.29M | 0.01% | 1856 |
|
|
2021
Q2 | $9.89M | Buy |
38,426
+31,232
| +434% | +$8.64M | 0.01% | 1922 |
|
|
2021
Q1 | $2.16M | Sell |
7,194
-34,195
| -83% | -$10.6M | ﹤0.01% | 3462 |
|
|
2020
Q4 | $10.6M | Buy |
41,389
+33,944
| +456% | +$8.77M | 0.01% | 1672 |
|
|
2020
Q3 | $1.85K | Buy |
7,445
+1,212
| +19% | +$381K | ﹤0.01% | 2657 |
|
|
2020
Q2 | $2.17M | Sell |
6,233
-2,699
| -30% | -$842K | ﹤0.01% | 2466 |
|
|
2020
Q1 | $2.39M | Sell |
8,932
-34,563
| -79% | -$10.7M | 0.01% | 1887 |
|
|
2019
Q4 | $14.1M | Sell |
43,495
-22,512
| -34% | -$6.53M | 0.02% | 1091 |
|
|
2019
Q3 | $18M | Buy |
+66,007
| New | +$24.2M | 0.03% | 847 |
|
|
2018
Q4 | – | Sell |
-56,547
| Closed | -$51.7M | – | 4044 |
|
|
2018
Q3 | $51.7M | Sell |
56,547
-41,359
| -42% | -$35.3M | 0.06% | 399 |
|
|
2018
Q2 | $71.7M | Buy |
97,906
+26,117
| +36% | +$30.1M | 0.09% | 269 |
|
|
2018
Q1 | $114M | Buy |
+71,789
| New | +$92.5M | 0.15% | 143 |
|
|
2017
Q2 | – | Sell |
-17,297
| Closed | -$6.09M | – | 3726 |
|
|
2017
Q1 | $6.09M | Sell |
17,297
-10,524
| -38% | -$2.37M | 0.01% | 1335 |
|
|
2016
Q4 | $5.12M | Sell |
27,821
-1,479
| -5% | -$301K | 0.01% | 1310 |
|
|
2016
Q3 | $7.55M | Buy |
29,300
+26,143
| +828% | +$6.73M | 0.01% | 1083 |
|
|
2016
Q2 | $674K | Sell |
3,157
-119,713
| -97% | -$26.8M | ﹤0.01% | 2345 |
|
|
2016
Q1 | $25.3M | Buy |
122,870
+49,546
| +68% | +$9.52M | 0.06% | 384 |
|
|
2015
Q4 | $18.5M | Sell |
73,324
-195,677
| -73% | -$40.2M | 0.04% | 607 |
|
|
2015
Q3 | $44.2M | Buy |
269,001
+242,661
| +921% | +$42.9M | 0.09% | 276 |
|
|
2015
Q2 | $4.94M | Sell |
26,340
-30,226
| -53% | -$5.2M | 0.01% | 1406 |
|
|
2015
Q1 | $9.33M | Buy |
56,566
+8,809
| +18% | +$1.81M | 0.02% | 1051 |
|
|
2014
Q4 | $11.1M | Buy |
47,757
+28,990
| +154% | +$6.2M | 0.02% | 922 |
|
|
2014
Q3 | $3.4M | Sell |
18,767
-8,579
| -31% | -$1.64M | 0.01% | 1520 |
|
|
2014
Q2 | $5.26M | Buy |
27,346
+16,601
| +154% | +$2.94M | 0.01% | 1188 |
|
|
2014
Q1 | $1.95M | Sell |
10,745
-1,027
| -9% | -$203K | 0.01% | 1808 |
|
|
2013
Q4 | $2M | Buy |
11,772
+6,521
| +124% | +$1.05M | 0.01% | 1821 |
|
|
2013
Q3 | $823K | Sell |
5,251
-16,719
| -76% | -$3.09M | ﹤0.01% | 2243 |
|
|
2013
Q2 | $3.81M | Buy |
+21,970
| New | +$3.37M | 0.01% | 1193 |
|
Other funds holding NKTR
BI
TSC
VCM
PM
AC
Millennium Management's NKTR Position: Q1 2026 in Review
Millennium Management reduced its Nektar Therapeutics (NKTR) stake by 11% in Q1 2026, selling an estimated $2.84M and leaving 404,277 shares worth $29.1M. The position accounts for 0.01% of the portfolio, ranked #1259.
Millennium Management first reported a position in NKTR in Q2 2013 and has held it in 45 quarters since. The position peaked at $114M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.
- Millennium Management held 404,277 shares of Nektar Therapeutics worth $29.1M as of Q1 2026.
- Millennium Management sold 49,798 Nektar Therapeutics shares in Q1 2026, an estimated $2.84M.
- Nektar Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1259 holding.
- Millennium Management first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 45 quarters since.
- Millennium Management's Nektar Therapeutics position peaked at $114M in Q1 2018.
- 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.
Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.